These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 12963575)

  • 1. Inappropriate fluoroquinolone use resulting from lack of specific guidelines.
    Luh JY; Karnath BM
    Arch Intern Med; 2003 Sep; 163(16):1978. PubMed ID: 12963575
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective.
    Low DE
    Clin Infect Dis; 2009 May; 48(10):1361-3. PubMed ID: 19348596
    [No Abstract]   [Full Text] [Related]  

  • 3. Community-acquired pneumonia.
    Luh JY; Karnath BM
    N Engl J Med; 2003 Apr; 348(14):1408-9; author reply 1408-9. PubMed ID: 12672875
    [No Abstract]   [Full Text] [Related]  

  • 4. Outpatient treatment of community-acquired pneumonia: evolving trends and a focus on fluoroquinolones.
    Carrie AG; Kozyrskyj AL
    Can J Clin Pharmacol; 2006; 13(1):e102-11. PubMed ID: 16585811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The United States guidelines for the management of community-acquired pneumonia and their relevance to Australasia.
    Waterer GW; Grayson ML
    Intern Med J; 2007 Dec; 37(12):789-91. PubMed ID: 18028080
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug not considered a first-line agent.
    Lexchin J
    Can Fam Physician; 1998 Nov; 44():2376. PubMed ID: 9839049
    [No Abstract]   [Full Text] [Related]  

  • 7. [Empiric therapy of community-acquired pneumonia: a transatlantic controversy].
    Garin N; Nendaz M
    Rev Med Suisse; 2006 Jan; 2(50):289-90, 292-4. PubMed ID: 16503046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis.
    Long R; Chong H; Hoeppner V; Shanmuganathan H; Kowalewska-Grochowska K; Shandro C; Manfreda J; Senthilselvan A; Elzainy A; Marrie T
    Clin Infect Dis; 2009 May; 48(10):1354-60. PubMed ID: 19348594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity.
    Singh A
    Clin Infect Dis; 2007 Jul; 45(1):133; author reply 134-5. PubMed ID: 17554716
    [No Abstract]   [Full Text] [Related]  

  • 10. Guideline tyranny: primum non nocere.
    Baum SG; Kaltsas A
    Clin Infect Dis; 2008 Jun; 46(12):1879-80. PubMed ID: 18462101
    [No Abstract]   [Full Text] [Related]  

  • 11. Approaches to treatment of community-acquired pneumonia in the emergency department and the appropriate role of fluoroquinolones.
    Moran G
    J Emerg Med; 2006 May; 30(4):377-87. PubMed ID: 16740445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should fluoroquinolones be first-line antibiotics in the treatment of community-acquired pneumonia in areas with high incidence of tuberculosis?
    Hsueh PR
    J Microbiol Immunol Infect; 2007 Oct; 40(5):386-7. PubMed ID: 17932596
    [No Abstract]   [Full Text] [Related]  

  • 13. [Anglo-Saxon guidelines for the treatment of community-acquired pneumonia also applicable in The Netherlands].
    Gyssens IC; Endtz HP
    Ned Tijdschr Geneeskd; 1997 Nov; 141(45):2200; author reply 2201-2. PubMed ID: 9550806
    [No Abstract]   [Full Text] [Related]  

  • 14. Approaches to treatment of community-acquired pneumonia in the emergency department and the appropriate role of fluoroquinolones.
    Schriger DL; Hoffman JR; Cooper RJ; Gupta M
    J Emerg Med; 2007 Aug; 33(2):197; discussion 197. PubMed ID: 17692777
    [No Abstract]   [Full Text] [Related]  

  • 15. Community-acquired pneumonia: the U.S. perspective.
    Niederman MS
    Semin Respir Crit Care Med; 2009 Apr; 30(2):179-88. PubMed ID: 19296418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of gemifloxacin in community-acquired pneumonia.
    Tillotson GS
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community-acquired pneumonia guidelines: Peering back through the looking glass...clearly?
    Peterson MW; Hornick DB
    Am J Med; 2004 Nov; 117(10):799-800. PubMed ID: 15541330
    [No Abstract]   [Full Text] [Related]  

  • 18. Community acquired pneumonia.
    Sargeant P
    Aust Fam Physician; 2004 Aug; 33(8):583; author reply 583. PubMed ID: 15373373
    [No Abstract]   [Full Text] [Related]  

  • 19. JCAHO/CMS core measures for community-acquired pneumonia.
    Fee C; Weber E; Sharpe BA; Nguy M; Quon T; Bookwalter T
    Ann Emerg Med; 2006 May; 47(5):505; author reply 506. PubMed ID: 16631994
    [No Abstract]   [Full Text] [Related]  

  • 20. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK; Triller DM; Yong CS; Lodise TP
    Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.